ATE513564T1 - Immunogener rekombinanter antikörper - Google Patents

Immunogener rekombinanter antikörper

Info

Publication number
ATE513564T1
ATE513564T1 AT04727885T AT04727885T ATE513564T1 AT E513564 T1 ATE513564 T1 AT E513564T1 AT 04727885 T AT04727885 T AT 04727885T AT 04727885 T AT04727885 T AT 04727885T AT E513564 T1 ATE513564 T1 AT E513564T1
Authority
AT
Austria
Prior art keywords
recombinant antibody
immunogenic recombinant
immunogenic
antibody
recombinant
Prior art date
Application number
AT04727885T
Other languages
English (en)
Inventor
Hans Loibner
Gottfried Himmler
Guenter Waxenecker
Manfred Schuster
Thomas Putz
Original Assignee
Altropus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altropus Gmbh filed Critical Altropus Gmbh
Application granted granted Critical
Publication of ATE513564T1 publication Critical patent/ATE513564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04727885T 2003-04-17 2004-04-16 Immunogener rekombinanter antikörper ATE513564T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0059903A AT500650B1 (de) 2003-04-17 2003-04-17 Immunogener rekombinanter antikörper
PCT/EP2004/004059 WO2004091655A2 (en) 2003-04-17 2004-04-16 Immunogenic recombinant antibody

Publications (1)

Publication Number Publication Date
ATE513564T1 true ATE513564T1 (de) 2011-07-15

Family

ID=33163428

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0059903A AT500650B1 (de) 2003-04-17 2003-04-17 Immunogener rekombinanter antikörper
AT04727885T ATE513564T1 (de) 2003-04-17 2004-04-16 Immunogener rekombinanter antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0059903A AT500650B1 (de) 2003-04-17 2003-04-17 Immunogener rekombinanter antikörper

Country Status (4)

Country Link
US (1) US8034338B2 (de)
EP (2) EP1613349B1 (de)
AT (2) AT500650B1 (de)
WO (1) WO2004091655A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1915394B1 (de) 2005-05-20 2021-01-27 Lonza Biologics plc. Expression auf hohem niveau von rekombinantem antikörper in einer säugetier-wirtszelle
EP2004695A2 (de) 2005-07-08 2008-12-24 Xencor, Inc. Optimierte anti-ep-cam-antikörper
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
WO2012154484A1 (en) * 2011-05-06 2012-11-15 Elwha Llc Compositions and methods for antibody and ligand identification
AU2014335720B2 (en) 2013-10-18 2019-08-01 Universidade Do Minho Peptide composition and uses thereof
WO2016003368A1 (en) * 2014-07-01 2016-01-07 Agency For Science, Technology And Research Optimized vectors for the production of recombinant proteins
US11365238B2 (en) 2015-12-07 2022-06-21 Camas Incorporated Sequencing chicken antibody repertoires following hyperimmunization and the identification of antigen-specific monoclonal antibodies
US11712410B2 (en) 2018-09-05 2023-08-01 K18, Inc. Composition for improving hair health
TW202216111A (zh) * 2020-07-03 2022-05-01 米尼奧大學 香氛釋放機制、方法及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5614610A (en) 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
AU7796291A (en) 1990-05-04 1991-11-27 Baxter Diagnostics Inc. High affinity antibodies to small peptides
US20020146410A1 (en) * 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
NZ252161A (en) 1992-05-22 1996-10-28 Sandoz Ltd Monoclonal murine internal image anti-idiotypic antibodies (ab2) to monoclonal antibodies br55 (ab1), their production and use in immunizing against hiv and epithelial and lung cancers
AU717779C (en) * 1994-12-28 2002-12-05 University Of Kentucky Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen
EP0857176A1 (de) 1995-10-25 1998-08-12 Centocor B.V. VON HUMANEM EPITHELANTIGEN Ep-CAM ABGELEITETE PEPTIDE UND IHRE ANWENDUNG
WO1997040140A1 (en) * 1996-04-22 1997-10-30 The Wistar Institute Of Anatomy And Biology Gd2 anti-idiotypic antibodies and uses thereof
AU4208897A (en) 1996-09-16 1998-04-02 Merck Patent Gmbh Oligocistronic expression system for the production of heteromeric proteins
CZ302801B6 (cs) 1999-01-13 2011-11-16 Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
PT1218504E (pt) 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
DE10059930A1 (de) 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AT502293B1 (de) 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
US20040181475A1 (en) * 2003-03-14 2004-09-16 Ejaz Haroon Preferred stock securitization process

Also Published As

Publication number Publication date
AT500650A1 (de) 2006-02-15
EP1613349A2 (de) 2006-01-11
US8034338B2 (en) 2011-10-11
WO2004091655A2 (en) 2004-10-28
EP2322214A1 (de) 2011-05-18
US20070258978A1 (en) 2007-11-08
AT500650B1 (de) 2009-11-15
EP1613349B1 (de) 2011-06-22
WO2004091655A3 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
EP1499352A4 (de) Rekombinante anti-interleukin-9-antikörper
DK1599504T3 (da) Modificeret antistof
NO20044347L (no) Anti-alfavbeta6-antistoff
DE602004022855D1 (de) Interleukin-10-antikörper
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
IS7547A (is) Ónæmisvaldandi samsetningar
DK1390066T3 (da) Vaccinesammensætning
NO20050132D0 (no) Vaksinesammensetning
EP1616881A4 (de) Anti-mpl-antikörper
IS7806A (is) Ónæmisvaldandi samsetning
NO20044326D0 (no) Virale antigener
DK1427444T3 (da) West-nil-vaccine
IS8387A (is) Ónæmisvaldandi samsetningar
NO20033882D0 (no) Vaksine
IS7831A (is) Bóluefni
EP1664117A4 (de) Immunogen
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1689869T4 (da) Rekombinant mikroorganisme
DE502004008321D1 (de) Bandaufwickelverfahren
DE60328408D1 (de) Impfstoff
EP1359932A4 (de) Tip39 polypeptide
NO20051561D0 (no) Vaksine
IS2922B (is) Bóluefni
DE60322070D1 (de) Rekombinante bcg-vakzine
DK1680502T3 (da) Rekombinant mikroorganisme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties